RESEARCH ARTICLE

Birth Weights in Sickle Cell Disease Pregnancies: A Cohort Study

Daveena Meeks1,2*, Susan E. Robinson3‡, David Macleod4‡, Eugene Oteng-Ntim1,4,5*

1 King’s College London School of Medicine, London, United Kingdom, 2 Department of Intensive Care and Anaesthetics, Royal Sussex County Hospital, Brighton, United Kingdom, 3 Department of Haematology, Guy’s and St. Thomas’ NHS Foundation Trust, London, United Kingdom, 4 London School of Hygiene and Tropical Medicine, London, United Kingdom, 5 Women’s Health Academic Centre, King’s College London and King’s Health Partners, St. Thomas’ Hospital, London, United Kingdom

* These authors contributed equally to this work.
‡ These authors also contributed equally to this work.
* Eugene.oteng-ntim@gstt.nhs.uk

Abstract

Pregnancy in women with Sickle Cell Disease (SCD) has been linked with an increased incidence of adverse foetal outcomes when compared to women without haemoglobinopathies (HbAA). There’s a paucity of data into foetal outcomes for infants born to women with SCD. Customised growth charts have been demonstrated to be better than population-based growth charts at identifying unhealthy small babies. We analysed the mean birth weight and customised birth weight centiles of infants born to mothers with SCD versus mothers with HbAA genotype, to quantify the risk of having a smaller baby. Birth weight and birth weight centiles were analysed for 88 women with SCD (50 HbSS; 38 HbSC) and 176 controls (HbAA). Statistically significant differences were seen in the mean birth weight (P value = 0.004) and the mean birth weight centiles (P value = 0.016). We conclude that SCD is a risk factor for having a smaller baby.

Introduction

The clinical care for Sickle Cell Disease (SCD) has vastly improved the quality and longevity of those affected. Pregnancies in this cohort, however, still carry a greater risk of unfavourable pregnancy outcomes [1]. The major types of SCD are: Sickle Cell Anaemia (HbSS), Sickle cell-Haemoglobin C disease (HbSC) and Sickle Cell β-Thalassaemia (HbSβthal) [2]. There is a paucity of data into foetal outcomes for infants born to women with SCD [3].

A meta-analysis of 26,823 SCD pregnancies (HbSS n = 1,523, HbSC n = 331, unspecified SCD genotype n = 24,969) showed a greater relative risk (RR) of small for gestational age (SGA) when analysed against women with normal haemoglobin (HbAA) (HbSS RR = 3.72, HbSC RR = 1.98) [1]. A Jamaican retrospective cohort of study of n = 118 HbSC and n = 110 HbAA pregnancies showed an increased rate of low birth weight (LBW) (HbSC 22.9%, HbAA 5.5%, p<0.0001) [4]. A UK nationwide cohort study of 109 SCD pregnancies (HbSS n = 55, HbSC n = 44, other SCD n = 11, unknown SCD genotype n = 3) based on data extracted from
the United Kingdom Obstetric Surveillance Study (UKOSS) showed an overall higher prevalence of LBW in babies born to mothers with SCD (23.3%, p < 0.001) compared to HbAA mothers, as well as an increased rate of LBW in babies born to HbSS versus HbSC mothers (HbSS 35.4%, HbSC 14%, p = 0.025) [5].

The existing data are based on population-based estimates, which do not adjust for the effect of maternal ethnicity and parity on birth weight [6,7]. The purpose of this study is to determine whether or not infants born to women with SCD are more prone to LWB, SGA and intrauterine growth restriction (IUGR) than infants born to women without SCD [2]. As far as we are aware, this study is novel in its use of customised birth weight growth charts to accurately investigate the relationship between maternal SCD and birth weight [8].

Materials and Methods

A retrospective cohort study was carried out on the birth weights of the newborns of mothers with SCD delivering at St Thomas’ Hospital between 2008–2013. St Thomas’ Hospital is a teaching hospital in London, UK which provides specialist tertiary care to a metropolitan patient population. Every pregnant woman receiving treatment at our department is offered and can opt to undergo haemoglobinopathy screening [8,9].

We looked at the influence of maternal SCD on birth weight, with reference to the following maternal physiological factors: body mass index (BMI), ethnicity and the number of previous births; and infant outcomes: sex and gestational age at birth. Data were extracted from an electronic clinical database (Terranova Healthware). The midwife attending the delivery had recorded data on the database. These data were used to generate a customised birth weight prediction, which was compared to the infant’s actual weight at birth using the UK Gardosi Bulk Centile Calculator Version 6.6 [8]. This version of the software uses the gestation related optimal weight standard (GROW) based specifically on the UK population [10].

Data were only included from singleton pregnancies, because pregnancies involving more than one foetus are susceptible to considerable foetal growth and weight differences [8,11]. In addition, only women with diagnosed SCD were included in the study population—those with sickle cell trait (SCT) were excluded. Pregnancies in women with SCT are not predisposed to impaired birth weight, as evidenced by a recent UK cohort study [8].

Customised growth chart calculators control for healthy growth variations due to: ethnicity, parity, maternal habitus, gender and gestational age at delivery. Population-based growth charts thus do not accurately distinguish between permissible (non-pathologically) and pathologically small neonates, whereas customised growth charts do [8]. Customised growth charts have been shown to be better at identifying small babies than population-based growth charts [6]. Data were analysed using the UK Gardosi customised growth chart calculator [8]. The UK Gardosi Bulk Centile Calculator predicts the Terminal Optimal Weight (the foetus’ growth potential) by incorporating the following physiological factors: maternal ethnicity, parity, height and weight at the time of booking, gestation at delivery (determined by ultrasound analysis) and the foetus’ gender and birth weight. These variables were extracted from Healthware and entered into the UK Gardosi Bulk Centile Calculator Version 6.6 to generate birth weight centiles [8,12].

Women were matched by age at delivery, parity and ethnicity to control for birth weight variations pertaining to ethnicity and parity. Although this is a cohort study, the matching allowed the control population to be as representative of the study population in as many aspects as could be controlled for, so as to enable any differences in the results to be representative of the difference in haemoglobin status rather than normal physiology [13]. The upper and lower limits of the birth weight centiles on the customised growth chart were used to more
accurately identify atypical growth. LBW is defined as weighing 2.5kg or less [8]. SGA describes neonates with a birth weight ranked at or below the 10th centile for gestation [7].

The study population incorporated all eligible women with SCD and the control population included all eligible women without SCD. The SCD group was stratified according to SCD type into HbSS and HbSC. Statistical analyses were made comparing SCD group against the control group, and the stratified HbSS and HbSC groups against the controls, using Stata 14. Given the heterogeneity of SCD, the purpose of the latter was to enable specific analysis of the impact on haemoglobin status on foetal growth [14].

Statistical differences and 95% confidence intervals were generated using logistic regression to analyse the birth weight and birth weight centiles in the study and control groups. Differences in the mean maternal age, BMI, gestational age and birth weight were estimated along with their 95% confidence intervals. T-value was performed to obtain the p-value for the difference, and the null hypothesis defined as a difference being equal to 0. For variables expressed as proportions (parity, sex, birth weight centile, LBW and SGA) we performed logistic regression to identify any differences in the proportions for the SCD and HbAA group [6,7,14,15].

Results

Birth weight and birth weight centiles were analysed for infants born to 88 women with SCD (50 with HbSS and 38 with HbSC genotype, respectively) and 176 controls (HbAA) (same ethnicity, age, parity and gestation) Table 1. Statistically significant differences were seen in mean birth weight (P value = 0.004) and mean birth weight centiles (P value = 0.016) Table 1. The mean age was 29.6 years in both the SCD group (28.5 years in HbSS; 31.0 years in HbSC groups) and control group (P value = 0.98). The mean BMI in the SCD group was 25.0 kg/m² (22.5 kg/m² in HbSS and 28.3 kg/m² in HbSC groups) and 27.3 kg/m² in the control group (P value = 0.003). There were no statistically significant differences in the rates of SGA or LBW amid the SCD and HbAA groups Table 2.

Table 1. Characteristics of study groups.

|                           | SCD (n = 88) | HbSS (n = 50) | HbSC (n = 38) | HbAA (n = 176) | Difference (SCD vs. HbAA) | P value
|---------------------------|--------------|---------------|---------------|-----------------|---------------------------|--------
| Maternal Age (years)*     | 29.6 (5.6)   | 28.5 (5.7)    | 31.0 (5.1)    | 29.6 (5.4)      | 0.02 (95% CI: -1.4,1.4)   | 0.98   |
| BMI (kg/m²)*              | 25.0 (6.2)   | 22.5 (3.2)    | 28.3 (7.6)    | 27.3 (5.5)      | 2.27 (95% CI: 0.79,3.75)  | 0.003  |
| Nulliparous (%)^          | 53.4%        | 60.0%         | 44.7%         | 52.8%           | 0.6%                      | 0.931  |
| Ethnicity (%)             |              |               |               |                 |                           |        |
| Black British             | 28.4%        | 30.0%         | 26.3%         | 28.4%           | 0                         | 1      |
| Black African             | 63.6%        | 66.0%         | 60.5%         | 63.6%           | 0                         | 1      |
| Black Other               | 8.0%         | 4.0%          | 13.2%         | 8.0%            | 0                         | 1      |
| Gestational age (weeks)*  | 38.3 (2.5)   | 38.1 (2.1)    | 38.5 (2.9)    | 38.7 (2.7)      | 0.44 (95% CI: -0.23,1.12) | 0.20   |
| Female infant (%)^        | 52.3%        | 62.0%         | 60.5%         | 50.6%           | 1.7%                      | 0.79   |
| Birth weight (g)*         | 2918 (587)   | 2858 (505)    | 2998 (678)    | 3176 (720)      | 258.4 (95% CI: 83.9,432.8) | 0.004  |
| Birth weight centile (%)* | 32.8 (24.3)  | 33.0 (23.7)   | 42.2 (32.1)   | 42.1 (32.1)     | 9.4 (95% CI: 1.8,17.1)    | 0.016  |
| LBW (%)                   | 15.9% (14)   | 18.4% (9)     | 14.0% (5)     | 10.8% (19)      | 5.1% (95% CI: -3.8, 14.0%)| 0.239  |
| SGA (%)                   | 23.9% (21)   | 18.0% (9)     | 31.6% (12)    | 20.5% (36)      | 3.4% (95% CI: -7.3, 14.1%)| 0.526  |

*Values are mean (SD)
^Statistically significant (P value <0.05)
^Logistic regression

SD = standard deviation *Matched variables—hence no statistically significant difference.

doi:10.1371/journal.pone.0165238.t001
The main differences between the SCD and control group were the mean birth weight and mean birth weight centile. The overall mean birth weight for the SCD pregnancies was 2918g compared to a mean birth weight of 3176g for the controls. The mean birth weight of the neonates born to SCD mothers was significantly lower at 258g below that of the HbAA counterparts (P value = 0.004). In keeping with this, the mean birth weight centile for the SCD deliveries (32.8th centile) was significantly lower than the controls (42.2nd centile) with a difference of 9.4 centiles (P value = 0.016) Table 1. The median birth weight was 3025g (interquartile range = 2740-3270g) for the SCD group and 3200g (interquartile range = 2890-3545g) for the controls.

The preterm birth rate (defined as birth prior to the 37th week of gestation) was 10.2% (n = 9) for the SCD group (95% CI = 5.3%-18.7%) and 9.1% (n = 16) for the control group (95% CI = 5.6%-14.4%) [1]. There was no significant difference between the ethnicities of our study and comparator group; however, this was to be expected given that we matched our control group according to ethnicity Table 1.

**Discussion**

**Key findings**

Statistically significant differences were seen in mean birth weight (P value = 0.004) and mean birth weight centiles (P value = 0.016). Inadequate foetal development and/or premature labour can cause LBW [16]. Babies born SGA are more susceptible to disease and death in utero or after birth. Affected infants may have impaired growth and/or cognitive development, and in adult life may be susceptible to heart and vascular problems [17]. Pregnancies in women with SCD are at increased risk of maternal mortality, pre-eclampsia, preterm delivery and stillbirth; such complications may prevent the developing foetus achieving its growth potential in utero [1,2].

**Interpretation of findings**

A neonate may exceed the threshold for SGA and still be growth restricted. IUGR reflects an infant who has been unsuccessful in attaining his or her personal optimal growth [13]. Our findings demonstrate that SCD deliveries are more at risk of smaller babies than non-SCD deliveries. There was no significant difference between the ethnicity, parity or age of the women in the SCD and control group, which further implicates SCD as the cause of the lower mean birth weight and mean birth weight centiles in the SCD group [7,18].

Gestational age at delivery is influenced by: maternal age at delivery, socioeconomic status, pathology, number of previous births, demographics, a history of preterm birth and smoking. Mothers of Black and Asian ethnicity have been shown to deliver earlier compared to white counterparts [19]. LBW has been linked with first-time mothers [20]. By matching our SCD population and controls, we ensured that there were no significant differences in the parity, gestational age at delivery, age or ethnicity of the women in our study population and matched

---

**Table 2. Adjusted Odds ratios for SCD versus HbAA.**

|                        | SCD (n = 88) | HbAA (n = 176) | Adjusted Odds ratio (SCD vs. HbAA) | P value

| LBW (%)^ &nbsp; &nbsp; &nbsp; | 15.9% (14)  | 10.8% (19)  | 1.56 (95% CI: 0.74, 3.29)  | 0.239
| SGA (%)^ &nbsp; &nbsp; &nbsp; | 23.9% (21)  | 20.5% (36)  | 1.22 (95% CI: 0.66, 2.25)  | 0.526

^Statistically significant (P value <0.05)
^Logistic regression.

doi:10.1371/journal.pone.0165238.t002

---
controls Table 1. Variations in these physiological factors are therefore unlikely to account for the statistically lower birth weight and birth weight centiles seen in our SCD group [19].

Our SCD group had a significantly lower mean BMI than our controls Table 1. Maternal BMI is an important consideration when assessing foetal growth, in particular birth weight. Women with a diagnosis of HbSS tend to have a lower body habitus than their HbAA counterparts. Our findings are consistent with this observation [15].

Alarming, a number of the controls were overweight (BMI between 25 and 29.9) or obese (BMI ≥30) [21]. The BMI difference has little statistical significance to the results, as the customised growth calculator takes maternal body habitus into consideration [13]. The findings do, however, highlight a separate issue of maternal obesity in this cohort and its implications on foetal outcomes [21].

Maternal obesity during pregnancy exposes the foetus to increased morbidity and mortality in the short- and long-term, including perinatal death and being large for gestational age (LGA) (at or above the 90th centile for birth weight for gestation at delivery and sex), and heart disease in later life, respectively [21,22]. Putting on weight is important during pregnancy for optimal foetal development. An Australian cohort study also using customised growth charts to quantify the relationship between increases in weight during pregnancy and birth weight demonstrated a significant relationship between extreme and insufficient increases in weight during gestation and higher rates of LGA and SGA, respectively [21]. Lower socioeconomic status has been correlated with poorer foetal outcomes. It is plausible, but unlikely, that this explains the statistical differences between the mean birth weights and mean birth weight centiles [11].

Babies born to black mothers have been shown to be more likely to be of LBW when compared to babies born to white mothers. A UK study quantified a 60% increased risk of LBW amongst black babies compared to white babies [22]. Customised growth charts adjust for ethnicity, which offers the aforementioned benefit of discerning pathologically from non-pathologically small babies [22,23].

Strengths and limitations of this study
The uniqueness of this study is that through the use of the customised growth chart we have more accurately ascertained the relationship between SCD and birth weight. As far as we are aware, this study is novel in its use of customised birth weight growth charts to accurately investigate the relationship between maternal SCD and birth weight [8].

Both active and passive smoking during pregnancy have been linked with IUGR. There was only one smoker in our SCD population, thus it is highly improbable that the significant growth restriction seen in our results relates to smoking as opposed to SCD [10].

The customised growth chart does not adjust for maternal or gestational pathologies, for example gestational hypertension which is known to affect birth weight [8,21]. Problems with the placenta, mother and/or foetus may underpin the reason for higher rates of IUGR in patients with SCD [7,18].

Clinical relevance and future areas of research
This study is the first to quantify the impact of SCD on birth weight and birth weight centiles using customised growth charts. The findings presented are therefore novel in that the analyses take into consideration the healthy differences, including maternal ethnic and anthropometric diversity, parity, gender and the stage of gestation at birth. Our study demonstrates that although SCD is a risk factor for smaller babies, adjustment for confounders and using the Gardosi customised growth chart still demonstrates a strong evidence of IUGR in women with
SCD in pregnancy. This has important clinical implications given the association between lower birth weight and unfavourable outcomes [6,7,15].

At present, we lack intrauterine interventions to cure IUGR. The identification of IUGR facilitates strategic timing of birth (e.g. induction) to optimise the baby’s prospects. Our findings emphasise the importance of regular detailed routine non-invasive monitoring for indicators of IUGR in the management of all SCD pregnancies [10].

Our study identifies several areas for future research. Firstly, problems with the placenta may underpin the IUGR [7,18]. The precise pathophysiology underlying the propensity for smaller babies in women with SCD remains elusive. The placenta plays a pivotal role in foetal development, providing a critical gateway between mother and child to supply nutrients, oxygen and other such growth enhancing components. Impairments in the placenta may have devastating effects on the health of the unborn child. Placental abnormalities have been proposed to be the basis for many foetuses failing to achieve their optimal growth. Vaso-occlusive crisis occurring in the placenta may bring about tissue ischemia and death, thus threatening the viability of the placenta [24]. Prolonged hypoperfusion and poor oxygenation are likely to impair the growth of the developing foetus [25]. Aberrant vascular remodelling has been shown to be central to the pathophysiology of preeclampsia [26]. Preeclampsia is fourfold more likely to occur in HbSS pregnancies [1].

Asymmetrical IUGR affecting the third trimester has been seen in SCD pregnancies [27]. A study using umbilical arterial doppler assessment to assess intrauterine growth in HbSS pregnancies demonstrated a relationship between increased arterial impedance and lower birth weight. These findings highlight a relationship between uteroplacental insufficiency and maternal SCD [28]. Uncovering the mechanisms behind the IUGR would be the cornerstone to developing preventative measures and interventions to improve placental function [29].

Secondly, the impact of SCD, notably HbSS on preconception BMI and pregnancy weight gain [21]. Thirdly, the significant risk of small babies in this patient cohort may have significant lifelong developmental implications on the offspring of women with SCD. Our study therefore flags up the importance of paediatric childhood developmental follow up of the offspring of this cohort of patients, especially given the hypothesis that future adult disease may be related to early life development—the Barker and the Developmental Origins of Adult Health and Disease theories [29].

This study is the first to quantify the impact of SCD on birth weight and birth weight centiles using customised growth charts. We conclude that SCD is a risk factor for smaller babies [6].

Acknowledgments

The authors would like to thank Mr Marcelo Canda for helping with data retrieval and Dr Benjamin Ayensah for his assistance with using the customised growth chart calculator.

Author Contributions

**Conceptualization:** EO D. Meeks SR.

**Formal analysis:** D. Meeks EO.

**Investigation:** D. Meeks.

**Methodology:** EO D. Meeks.

**Project administration:** EO D. Meeks.
Resources: EO SR.
Software: D. Macleod.
Supervision: EO.
Validation: D. Macleod.
Visualization: D. Meeks.
Writing – original draft: D. Meeks EO.
Writing – review & editing: D. Meeks EO.

References
1. Oteng-Ntim E, Meeks D, Webster L, Howard J, Doyle P, Chappell L. Adverse Maternal and Perinatal Outcomes in Pregnant Women with Sickle Cell Disease: Systematic Review and Meta-analysis. Blood. 2015. 125, 21, 3316–25. doi: 10.1182/blood-2014-11-607317 PMID: 25800049
2. Macmullen NJ and Dulska L A. Perinatal implications of sickle cell disease. MCN, American Journal of Maternal Child Nursing. 2011. 36, 232–8; quiz 239–40. doi: 10.1097/NMC.0b013e3182182215 PMID: 21709519
3. Howard J and Oteng-Ntim E. The obstetric management of sickle cell disease. Best Practice & Research Clinical Obstetrics and Gynaecology. 2012. 26, 25–36.
4. Thame M M, Singh-Minott I, Osmond C, Melbourne-Chambers R H, Serjeant G R. Pregnancy in sickle cell-haemoglobin C (SC) disease. A retrospective study of birth size and maternal weight gain. European Journal of Obstetrics and Gynecology & Reproductive Biology. 2016. 203, 16–19.
5. Oteng-Ntim E, Ayensah B, Knight M, Howard J. Pregnancy outcomes in patients with sickle cell disease in the UK—a national cohort study comparing sickle cell anaemia (HbSS) with HbSC disease. British Journal of Haematology. 2015. 169 (1), 129–37. doi: 10.1111/bjh.13270 PMID: 25522142
6. Gardosi J and Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles. American Journal of Obstetrics & Gynecology. 2009. 201, 28.e1–28.e8.
7. Carberry A E, Gordon A, Bond D M, Hyett J, Raynes-Greenow C H, and Jeffery H E. Customised versus population-based growth charts as a screening tool for detecting small for gestational age infants in low-risk pregnant women. Cochrane Database of Systematic Reviews. 2011. Cd008549. doi: 10.1002/14651858.CD008549.pub2 PMID: 22161432
8. Tan T L, Seed P and Oteng-Ntim E. Birthweights in sickle cell trait pregnancies. An International Journal of Obstetrics & Gynaecology. 2008. 115, 1116–1121.
9. Streetly A. Standards for the linked Antenatal and Newborn Screening Programme. NHS Sickle Cell & Thalassaemia Screening Programme. 2011.
10. Gardosi J, Madurasinghe V, Williams M, Malik A, Francis A. Maternal and fetal risk factors for stillbirth: population based study. British Medical Journal. 2013. 346, f108. doi: 10.1136/bmj.f108 PMID: 23349424
11. Centre for Maternal and Child Enquiries (CMACE) Perinatal Mortality 2009: United Kingdom. CMACE: London, 2011
12. Gardosi J. Customised assessment of fetal growth potential: implications for perinatal care. Archives of Disease in Childhood Fetal Neonatal Edition. 2012. 97, F314–7. doi: 10.1136/fetalneonatal-2012-301708 PMID: 22684160
13. Clausson B, Gardosi J, Francis A, Cnattingius S. Perinatal outcome in SGA births defined by customised versus population-based birthweight standards. An International Journal of Obstetrics and Gynaecology. 2001. 108, 830–4.
14. Brocklehurst P, Hardy P, Hollowell J, Linsell L, Macfarlane A, McCartney C et al. Perinatal and maternal outcomes by planned place of birth for healthy women with low risk pregnancies: the Birthplace in England national prospective cohort study. British Medical Journal. 2011. 343, d7400. doi: 10.1136/ bmj.d7400 PMID: 22117057
15. Thame M M, Osmond C and Serjeant G R. Fetal growth in women with homozygous sickle cell disease: an observational study. European Journal of Obstetrics & Gynecology & Reproductive Biology. 2013. 170, 62–6.
16. Sweet D. Statistical bulletin: Infant and Perinatal Mortality in England and Wales by Social and Biological Factors. Office for National Statistics. 2012.

17. Grivell R M, Wong L, Bhatia V. Regimens of fetal surveillance for impaired fetal growth. Cochrane Database of Systematic Reviews. 2012. 6, Cd007113. doi: 10.1002/14651858.CD007113.pub3 PMID: 22696366

18. Patel R R, Steer P, Doyle P, Little M P, Elliott P. Does gestation vary by ethnic group? A London-based study of over 122,000 pregnancies with spontaneous onset of labour. International Journal of Epidemiology. 2004. 33, 107–13. doi: 10.1093/ije/dyg238 PMID: 15075154

19. Miranda M L, Edwards S E, Myers E R. Adverse birth outcomes among nulliparous vs. multiparous women. Public Health Reports. 2011. 126, 797–805. PMID: 22043095

20. Chung J G, Taylor R S, Thompson J M, Anderson N H, Dekker G A, Kenny L et al. Gestational weight gain and adverse pregnancy outcomes in a nulliparous cohort. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013, 167, 149–53.

21. Chappell L C, Seed P T, Myers J, Taylor R S, Kenny L C, Dekker G A, et al. Exploration and confirmation of factors associated with uncomplicated pregnancy in nulliparous women: prospective cohort study. British Medical Journal. 2013. 347, f6398. doi: 10.1136/bmj.f6398 PMID: 24270055

22. Kelly Y, Panico L, Bartley M, Marmot M, Nazroo J, Sacker A. Why does birthweight vary among ethnic groups in the UK? Findings from the Millennium Cohort Study? Journal of Public Health. 2008. 31, 131–137. doi: 10.1093/pubmed/fdn057 PMID: 18647751

23. Rathod K B, Jaiswal K N, Shrivastava A C, Shrikhande A V. Study of placenta in sickle cell disorders. Indian Journal of Pathology and Microbiology. 2007. 50, 698–701. PMID: 18306531

24. Balihallimath R L, Shirol V S, Gan A M, Tyagi N K, Bandankar M R. Placental morphometry determines the birth weight. Journal of Clinical and Diagnostic Research. 2013. 7, 2428–31. doi: 10.7860/JCDR/2013/7478.3564 PMID: 24392363

25. Elenga N, Adeline A, Balcaen J, Vaz T, Calvez M, Terraz A, et al. Pregnancy in sickle cell disease is a very high-risk situation: an observational study. Obstetrics and Gynecology International. 2016. 9069054. doi: 10.1155/2016/9069054 PMID: 27403164

26. Hawfield A and Freedman B I. Pre-eclampsia: the pivotal role of the placenta in its pathophysiology and markers for early detection. Therapeutic Advances in Cardiovascular Disease. 2008. 3 (1), 65–73. doi: 10.1177/1753944708097114 PMID: 19124387

27. Yu C K, Stasiowska E, Stephens A, Awogbade M, Davies A. Journal of Obstetrics and Gynaecology. 2009. 29 (6), 512–6. doi: 10.1080/01443610903003175 PMID: 19697199

28. Billett H H, Langer O, Regan O T, Merkatz I, Anyaegbunam A. American Journal of Hematology. 1993. 42 (3), 305–8. PMID: 7679883

29. Armitage J A, Poston L, Taylor P D. Developmental origins of obesity and the metabolic syndrome: the role of maternal obesity. Frontiers of Hormone Research. 2008. 36, 73–84. PMID: 18290895